GlassScriptPhysician profile
Tiffany J Matragas
NPI 1801081716
$6,176.75
in general payments reported to CMS, 2019-2025
27 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what 95% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.60 · 2022: $183 · 2023: $1,751 · 2024: $2,356 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,646 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,646.24 |
| Education | $332.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,833.49 | 2022-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,083.91 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $321.08 | 2022-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $298.53 | 2022-2025 | Saphnelo |
| Horizon Therapeutics Plc | $245.28 | 2023 | Tepezza |
| Amgen INC. | $239.29 | 2023-2025 | Prolia, Evenity, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $183.18 | 2024-2025 | Orencia |
| Pacira Pharmaceuticals Incorporated | $162.76 | 2023-2024 | Zilretta, Iovera |
| Aurinia Pharma U.S., INC. | $162.67 | 2022-2025 | Lupkynis |
| Ucb, INC. | $96.39 | 2023-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $84.12 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $61.46 | 2022-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $58.72 | 2024 | Voquezna |
| Lilly USA, LLC | $47.62 | 2023-2024 | Taltz, Olumiant |
| Mallinckrodt Hospital Products INC. | $43.12 | 2023-2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $32.89 | 2022-2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $31.77 | 2022 | |
| Genentech USA, INC. | $31.71 | 2024 | Actemra |
| Collegium Pharmaceutical, INC. | $30.90 | 2023 | Belbuca |
| Organon LLC | $18.63 | 2025 | Hadlima, Renflexis |
| Tonix Medicines, INC. | $18.24 | 2025 | Tonmya |
| Genzyme Corporation | $17.66 | 2024 | |
| Allergan, INC. | $15.60 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.23 | 2025 | |
| Invivyd INC | $15.16 | 2025 | Pemgarda |
| Sobi, INC | $14.00 | 2022 | |
| Celltrion USA INC. | $13.34 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Matragas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.